AKTX vs GILD · $17.2M cap vs P/E 18, rev $7.80B
Akari Therapeutics PLC (AKTX) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
Akari Therapeutics PLC (AKTX) is a biotechnology company listed on US.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US. It is led by Daniel P. O'Day.
AKTX does not have a complete income-statement cache yet.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
AKTX currently screens at market cap $17.2M. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the AKTX and GILD stock pages for the full models.
Not investment advice.